Rural 340B Access Act of 2025

U.S. Congress · HR44 · In Committee

What the bill says

HR44 · U.S. Congress · In Committee

Introduced 2025-01-03. Latest action: Referred to the House Committee on Energy and Commerce.

View on Congress.gov →

Summary (plain-language)

Rural 340B Access Act of 2025 This bill makes rural emergency hospitals (REHs) eligible to purchase drugs from manufacturers at discounted prices by participating in the Health Resources and Services Administration’s (HRSA’s) 340B drug pricing program. HRSA’s 340B program requires drug manufacturers that participate in the Medicaid program to sell certain outpatient drugs at discounted prices to entities listed as eligible under current law. Additionally, in 2020, Congress established REHs as a new Medicare provider designation for hospitals in rural areas providing emergency department services, observation care, and other outpatient medical and health services for which the annual per patient average length of stay does not exceed 24 hours. The bill adds qualifying REHs to the list of entities that are eligible to participate in the 340B program.

Sponsors

Text versions

  • Introduced in House — 2025-01-03 — XML

What analysts say

No nonpartisan analysis on file for this measure yet.

What politicians say

No linked claims or utterances yet — no one on record has cited this measure to justify a public argument.

Action History

DateAction
2025-01-03Introduced in House
2025-01-03Referred to the House Committee on Energy and Commerce.

Lobbying on this bill

Showing 1 of 1 bill mention.

Honesty note: each filer below disclosed lobbying on this bill — that much the filing tells us. But the dollar figure is their total lobbying spend for the whole quarter across all their issues, not the amount spent on this bill, and the filing never says whether they supported or opposed it.

Registrant (lobbying firm)ClientPeriodReported quarterly amountExtraction
340B HEALTH 340B HEALTH Q1 2026 $337,176 Explicit

Source: Senate LDA filings.